Skip to content

Dyne Therapeutics, Inc.

DYN Nasdaq SEC CIK 1818794

Follow Dyne Therapeutics Weekly email: filings, results, news

News

5 stories filed under Dyne Therapeutics, grouped into ongoing threads

Trial

Thread · 2 stories

Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class

Markets 15 d ago also on NVS

Raymond James cuts Dyne Therapeutics price target on DM1 trial risk

Markets 16 d ago

More coverage

Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed

Markets 16 d ago

Why is Dyne Therapeutics stock plummeting today?

Markets 16 d ago

Dyne therapeutics director Jason Rhodes sells $65.2m of common stock

Markets 37 d ago

Profile

Headquarters: WALTHAM, MA, United States
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

News · 5 stories clustered from the RSS aggregator